Management of Covid-19 Disease in Pediatric Oncology Patients
Pediatric cancer patients are immunocompromised, and the risks are higher in this population. Confirmed cases are defined as PCR (polymerase chain reaction) positive patients. The severity of infection is divided into four groups: asymptomatic/mild, moderate, severe, and critical, based on the clini...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/78445 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1879164743840694272 |
|---|---|
| author | Cakmak, Hatice Mine |
| author_browse | Cakmak, Hatice Mine |
| author_facet | Cakmak, Hatice Mine |
| author_sort | Cakmak, Hatice Mine |
| building | IntechOpen |
| collection | Acceso abierto |
| description | Pediatric cancer patients are immunocompromised, and the risks are higher in this population. Confirmed cases are defined as PCR (polymerase chain reaction) positive patients. The severity of infection is divided into four groups: asymptomatic/mild, moderate, severe, and critical, based on the clinical, laboratory, and radiological features. In the pediatric population, the COVID-19 disease has a mild course. Chemotherapy courses can be interrupted according to the symptoms and severity of the disease. Azithromycin, antivirals are used as a single agent or in combination. In critical patients, convalescent plasma, mesenchymal stem cells, tocilizumab, and granulocyte transfusions are administered. In recent studies, having hematological malignancy, stem cell transplantation, a mixed infection, and abnormal computerized tomography findings increase the severity of the disease and the need for an intensive care unit. Therefore, the patients and their families should be aware of a higher risk of severe forms than immunocompetent children. |
| doi_str_mv | 10.5772/intechopen.100004 |
| first_indexed | 2026-10-15T21:39:12Z |
| format | Book Chapter |
| fullrecord | <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><identifier>intech-78445</identifier><datestamp>2021-09-05</datestamp>
<dc:title>Management of Covid-19 Disease in Pediatric Oncology Patients</dc:title>
<dc:creator>Hatice Mine Cakmak</dc:creator>
<dc:subject>Health Sciences</dc:subject>
<dc:description>Pediatric cancer patients are immunocompromised, and the risks are higher in this population. Confirmed cases are defined as PCR (polymerase chain reaction) positive patients. The severity of infection is divided into four groups: asymptomatic/mild, moderate, severe, and critical, based on the clinical, laboratory, and radiological features. In the pediatric population, the COVID-19 disease has a mild course. Chemotherapy courses can be interrupted according to the symptoms and severity of the disease. Azithromycin, antivirals are used as a single agent or in combination. In critical patients, convalescent plasma, mesenchymal stem cells, tocilizumab, and granulocyte transfusions are administered. In recent studies, having hematological malignancy, stem cell transplantation, a mixed infection, and abnormal computerized tomography findings increase the severity of the disease and the need for an intensive care unit. Therefore, the patients and their families should be aware of a higher risk of severe forms than immunocompetent children.</dc:description>
<dc:publisher>IntechOpen</dc:publisher>
<dc:date>2021-09-05</dc:date>
<dc:type>Chapter, Part Of Book</dc:type>
<dc:identifier>https://www.intechopen.com/chapters/78445</dc:identifier>
<dc:identifier>doi:10.5772/intechopen.100004</dc:identifier>
<dc:language>en</dc:language>
<dc:relation>ISBN:978-1-83968-755-6</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/3.0/</dc:rights>
<dc:source>https://www.intechopen.com/books/10535 ; SARS-CoV-2 Origin and COVID-19 Pandemic Across the Globe</dc:source>
</oai_dc:dc> |
| id | intech-78445 |
| institution | IntechOpen |
| isbn | 978-1-83968-755-6 |
| language | English |
| last_indexed | 2026-10-15T21:39:12Z |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | oai_dc |
| spelling | intech-784452021-09-05 Management of Covid-19 Disease in Pediatric Oncology Patients Hatice Mine Cakmak Health Sciences Pediatric cancer patients are immunocompromised, and the risks are higher in this population. Confirmed cases are defined as PCR (polymerase chain reaction) positive patients. The severity of infection is divided into four groups: asymptomatic/mild, moderate, severe, and critical, based on the clinical, laboratory, and radiological features. In the pediatric population, the COVID-19 disease has a mild course. Chemotherapy courses can be interrupted according to the symptoms and severity of the disease. Azithromycin, antivirals are used as a single agent or in combination. In critical patients, convalescent plasma, mesenchymal stem cells, tocilizumab, and granulocyte transfusions are administered. In recent studies, having hematological malignancy, stem cell transplantation, a mixed infection, and abnormal computerized tomography findings increase the severity of the disease and the need for an intensive care unit. Therefore, the patients and their families should be aware of a higher risk of severe forms than immunocompetent children. IntechOpen 2021-09-05 Chapter, Part Of Book https://www.intechopen.com/chapters/78445 doi:10.5772/intechopen.100004 en ISBN:978-1-83968-755-6 https://creativecommons.org/licenses/by/3.0/ https://www.intechopen.com/books/10535 ; SARS-CoV-2 Origin and COVID-19 Pandemic Across the Globe |
| spellingShingle | Health Sciences Cakmak, Hatice Mine Management of Covid-19 Disease in Pediatric Oncology Patients |
| title | Management of Covid-19 Disease in Pediatric Oncology Patients |
| title_full | Management of Covid-19 Disease in Pediatric Oncology Patients |
| title_fullStr | Management of Covid-19 Disease in Pediatric Oncology Patients |
| title_full_unstemmed | Management of Covid-19 Disease in Pediatric Oncology Patients |
| title_short | Management of Covid-19 Disease in Pediatric Oncology Patients |
| title_sort | management of covid 19 disease in pediatric oncology patients |
| topic | Health Sciences |
| url | https://www.intechopen.com/chapters/78445 |
| work_keys_str_mv | AT cakmakhaticemine managementofcovid19diseaseinpediatriconcologypatients |